An announcement from Tonix Pharma (TNXP) is now available.
The Company has successfully aligned with the FDA on key aspects regarding Tonmya™, a drug candidate for managing fibromyalgia, after completing its final pre-New Drug Application meeting. Enthusiasm is growing as the company awaits the formal minutes, which could signal significant progress towards commercializing the drug. These developments are particularly exciting for investors as they could potentially indicate upcoming milestones and growth opportunities in the pharmaceutical sector.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
